Last Updated: November 19, 2026

Details for Patent: 7,470,433

« Back to Dashboard


Summary for Patent: 7,470,433
Title:Formulations for transdermal or transmucosal application
Abstract:The present invention relates generally to formulations for transdermal or transmucosal administration of an active agent such as estradiol. The invention is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters.
Inventor(s):Dario Norberto R. Carrara, Arnaud Grenier, Celine Besse, Stephen M. Simes, Leah M. Lehman
Assignee: Antares Pharma IPL AG
Application Number:US11/693,988
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Delivery;
Patent landscape, scope, and claims:

US Patent 7,470,433: Scope, Claim Analysis, Expiration, and Estradiol Gel Patent Landscape

US Patent No. 7,470,433 covers estrogen-containing transdermal or transmucosal gels using ethanol or another C2-C4 alkanol, a polyalcohol, and a diethylene glycol monoalkyl ether permeation enhancer. The patent is directed primarily to estradiol gel formulations that exclude progestins and long-chain fatty excipients. Its commercial relevance is closely associated with estrogen gel products such as Elestrin.

The core technical combination is:

  • Estrogen, particularly estradiol.
  • A gel-forming polymer.
  • A C2-C4 alkanol, principally ethanol.
  • A polyalcohol, principally propylene glycol.
  • Diethylene glycol monoethyl ether, commonly known as Transcutol.
  • Substantial exclusion of long-chain fatty alcohols, fatty acids, and fatty esters.
  • No progestin.

The patent’s commercial blocking value depends on whether a competing product practices the claimed excipient combination, not merely whether it contains estradiol.

What does US Patent 7,470,433 protect?

The patent protects composition-of-matter claims directed to estrogen gels for delivery through skin or mucosal tissue. It does not claim estradiol as a molecule. Estradiol is an old active pharmaceutical ingredient. The claimed subject matter is the formulation architecture and excipient relationship.

Claim 1 is the principal broad independent claim. A product must contain all of the following elements to fall within its literal scope:

Claim element Required feature
Dosage form Gel
Route Transdermal or transmucosal
Active agent At least one estrogen
Gelling agent Required
Alkanol C2-C4 alkanol
Polyalcohol Required
Permeation enhancer Monoalkyl ether of diethylene glycol
Functional limitation Enhances estrogen permeation
Exclusion Substantially free of specified long-chain fatty compounds
Exclusion No progestin

The claim does not require a specific estrogen concentration, daily dose, carbomer grade, pH, or commercial delivery volume. Those limitations appear in dependent claims.

How broad is independent claim 1?

Claim 1 is broad because it covers a genus of estrogen gels rather than one specific formula. The claim reaches formulations containing:

  • Estradiol and other estrogenic agents.
  • Ethanol, isopropanol, or n-propanol, provided the alkanol falls within the C2-C4 limitation.
  • Various polyalcohols, including propylene glycol and potentially other polyhydric alcohols.
  • Monoalkyl ethers of diethylene glycol.
  • A wide range of gelling agents.

The claim is narrower than a general claim to all estradiol gels. A formulation that uses estradiol but lacks diethylene glycol monoethyl ether would not literally satisfy claim 1. The same is true for a formulation containing a progestin, depending on how the “provided that a progestin is not present” limitation is construed.

The phrase “substantially free of long-chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters” creates an additional limitation. A competing product containing a small amount of a fatty excipient would require a fact-specific analysis of whether the amount is inconsistent with the claimed substantial absence.

What formulations are protected by claims 2 through 12?

Claims 2 through 12 progressively narrow the formulation by concentration, dose, excipient identity, and manufacturing composition.

Claim Principal limitation Practical significance
2 Estrogen at 0.01%-10%; daily dose 0.625-2.5 g Covers broad concentration and application ranges
3 About 0.06% estrogen; 1.25-2.5 g daily Closely tracks commercial estradiol gel dosing
4 Enumerated estrogen species Defines a broad estrogen Markush group
5 Vehicle concentration ranges Establishes excipient ratio boundaries
6 Alkanol 20%-65%; polyalcohol 1%-15%; enhancer 1%-15% Narrows to commercially practical gel compositions
7 Ethanol, isopropanol, or n-propanol; polypropylene glycol More specific vehicle formulation
8 Polyalcohol-to-enhancer ratio of 1.25:1 to 1.2:1; gelling and neutralizing agents; water Detailed formulation limitation
9 Optional formulation excipients Adds conventional pharmaceutical ingredients
10 Specific gelling and buffering systems Covers carbomers and other polymeric gel systems
11 Active agent is estradiol Key species-specific claim
12 Example formula Closest claim to a defined commercial composition

Claim 12 is particularly important because it recites a formula containing:

  • 0.01%-1% estradiol.
  • 1.2% carbomer 940.
  • 0.4% triethanolamine.
  • 46.28% alcohol.
  • 6% propylene glycol.
  • 5% diethylene glycol monoethyl ether.
  • 0.06% disodium EDTA.
  • Purified water to volume.

The claim uses “alcohol” rather than expressly limiting the ingredient to ethanol. The specification and surrounding claims would be relevant to determining whether “alcohol” in claim 12 is limited by the C2-C4 alkanol language appearing elsewhere in the claim set.

How do claims 13 through 18 differ from claims 1 through 12?

Claims 13 through 18 form a second claim set with a narrower and more commercially recognizable excipient combination.

Claim 13 expressly requires:

  • Estrogen.
  • A gelling agent.
  • Ethanol.
  • Propylene glycol.
  • Diethylene glycol monoethyl ether.
  • The same long-chain fatty-compound exclusion.
  • No progestin.

The key distinction is that claim 13 identifies the three principal vehicle components by name or specific class:

Component Claim 13 requirement
Alkanol Ethanol, 5%-75% of the vehicle
Polyalcohol Propylene glycol, 1%-30% of the vehicle
Permeation enhancer Diethylene glycol monoethyl ether, 0.2%-25% of the vehicle

Claims 14 through 18 then narrow estrogen content, dosage, formulation percentages, and active ingredient.

Claim 18 is the most detailed claim in this group. It covers a composition containing:

  • 0.01%-2% estradiol.
  • 0.05%-4% carbomer.
  • 0.05%-1% triethanolamine.
  • 20%-65% alcohol.
  • 1%-15% propylene glycol.
  • 1%-15% diethylene glycol monoethyl ether.
  • 20%-65% purified water.

Claims 13 and 18 are more vulnerable to design-around than claim 1 because they specify ethanol, propylene glycol, and diethylene glycol monoethyl ether. A competitor could potentially avoid literal infringement by replacing one of those components, although the doctrine of equivalents would remain relevant.

What is the likely claim construction of “monoalkyl ether of diethylene glycol”?

The phrase generally covers compounds formed by etherification of one hydroxyl group of diethylene glycol with an alkyl group. Diethylene glycol monoethyl ether is the principal example and is commonly identified as Transcutol or ethoxydiglycol.

Claim 13 and claim 18 remove much of the interpretive dispute by expressly naming diethylene glycol monoethyl ether. Claim 1 is broader because it covers the class rather than only the ethyl ether.

A formulation using diethylene glycol monomethyl ether could potentially fall within claim 1 if the compound satisfies the claim construction and performs the claimed permeation-enhancing function. It would not necessarily satisfy claim 13 or claim 18, which expressly require the monoethyl ether.

What is the significance of the “no progestin” limitation?

The exclusion of progestins limits the patent to estrogen-only formulations. A combined estrogen-progestin product would have a non-infringement position against claims containing the express exclusion, assuming the product actually contains a progestin as part of the marketed formulation.

This limitation separates the claimed formulations from combination hormone-replacement products containing estrogen plus progesterone or a synthetic progestin. It also creates a potential design-around route for products that combine estradiol with a progestin, although regulatory, clinical, and formulation considerations may make that route commercially unattractive.

The exclusion also limits the patent’s relevance to estrogen-only products such as estradiol gels. It does not prevent infringement by a formulation that contains other non-progestin active agents unless those ingredients alter the claim analysis.

What are the principal validity issues?

The patent’s validity risk would turn on the prior art and prosecution history. The principal legal pressure points are predictable from the claim structure.

Obviousness under 35 U.S.C. § 103

The combination of ethanol, propylene glycol, carbomer, water, and a glycol ether permeation enhancer may be challenged as an obvious formulation optimization if earlier references disclose:

  • Estradiol gels.
  • Alcohol-based transdermal vehicles.
  • Propylene glycol as a cosolvent or humectant.
  • Diethylene glycol monoethyl ether as a permeation enhancer.
  • Carbomer-based gel systems.

The strongest patentability argument would likely rely on the combined performance of the excipient system, including adequate estradiol delivery while avoiding odor and irritation attributed to long-chain fatty excipients. Unexpected permeation, stability, tolerability, or dose performance could support non-obviousness under the standards applied to pharmaceutical formulations.

Written description and enablement

Claims 1 and 4 cover broad estrogen and vehicle classes. A challenger could argue that the specification does not adequately support the full scope of every claimed estrogen, every C2-C4 alkanol, every polyalcohol, and every monoalkyl ether of diethylene glycol.

The narrower estradiol claims are generally less exposed because the specification and examples appear directed to estradiol gel products. The broad Markush claims present a larger genus-support question.

Indefiniteness

Potentially disputed terms include:

  • “Substantially free.”
  • “Long-chain.”
  • “Sufficient to provide permeation enhancement.”
  • “About.”
  • “Alcohol” in claim 12.
  • “Vehicle” when percentage ranges are expressed relative to the vehicle rather than the entire formulation.

The functional permeation limitation may be construed in light of the specification and testing data. “Substantially free” is not automatically indefinite, but the intrinsic record would be important in determining the quantitative boundary.

Written errors and claim clarity

Claim 13 contains the phrase “long-chain fatty” at the end of the exclusion, apparently omitting “esters.” That textual defect would likely be evaluated under claim-construction and correction principles. The surrounding language and corresponding claims may support correction if the intended meaning is apparent. The error could still create litigation leverage.

When did US Patent 7,470,433 expire?

The patent issued on December 30, 2008. Its enforceable term is governed by the 20-year term rules under 35 U.S.C. § 154, measured from the applicable nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other USPTO-recorded events [1].

Public patent records associate the patent with the BioSante estrogen-gel formulation program and an expiration period in the mid-2020s. The patent should not be treated as currently enforceable without checking the USPTO Patent Center record for the exact term-adjustment calculation and any recorded extension or disclaimer [2].

For commercial diligence, the relevant conclusion is that the patent’s remaining-life value is limited or exhausted, depending on the applicable term calculation and the date of review. FDA marketing exclusivity and patent enforceability are separate issues. FDA exclusivity does not extend the patent term, and patent expiration does not itself establish FDA approval of a generic product.

What is the Orange Book status of the patent?

The Orange Book identifies patents submitted by NDA sponsors and accepted for listing against approved drug products. Listing does not establish that every claim is valid or infringed. It creates a statutory certification framework for ANDA applicants under the Hatch-Waxman Act [3, 4].

For an estradiol gel product associated with this patent, the commercial questions are:

  1. Whether US 7,470,433 is listed against the relevant NDA.
  2. Whether the listing remains active.
  3. Whether the patent is identified as a drug-substance, drug-product, or method-of-use patent.
  4. Whether any pediatric extension or other term adjustment applies.
  5. Whether the NDA sponsor has submitted a current patent declaration or delisting request.

The patent is principally a drug-product or formulation patent. It is not a patent to the estradiol active ingredient itself. A listed formulation patent can require an ANDA applicant to make a Paragraph IV certification even when the active ingredient is old.

What Paragraph IV challenge risks exist?

A generic estradiol gel applicant seeking approval before listed patent expiry would generally evaluate four certification options:

Certification Meaning
Paragraph I No patent information has been submitted
Paragraph II Listed patent has expired
Paragraph III Applicant will wait until patent expiry
Paragraph IV Listed patent is invalid, unenforceable, or not infringed

A Paragraph IV notice can trigger patent litigation under 21 U.S.C. § 355(j)(5)(B)(iii). A timely infringement action can impose a 30-month stay of ANDA approval, subject to statutory exceptions [4].

For this patent, a Paragraph IV strategy would likely focus on:

  • Non-infringement through substitution of the permeation enhancer.
  • Use of a different alcohol or polyalcohol.
  • Inclusion of a progestin, where clinically and regulatorily appropriate.
  • A formulation outside the claimed concentration ranges.
  • Invalidity based on obviousness over prior transdermal estrogen and permeation-enhancer references.
  • Indefiniteness or lack of written description for broad claim language.

Because the active ingredient is estradiol, an ANDA applicant would not face biosimilar requirements. The product would generally proceed under the generic-drug framework if it can demonstrate pharmaceutical equivalence, bioequivalence, and compliance with the relevant topical/transdermal product requirements.

What is the biosimilar risk for this patent?

There is no conventional biosimilar pathway for estradiol. Estradiol is a small-molecule active ingredient, not a biological product. The relevant competitive pathway is an ANDA or, depending on product differences, a 505(b)(2) application.

The patent therefore creates generic formulation risk rather than biosimilar risk. A 505(b)(2) applicant could rely partly on FDA findings for an existing estradiol product while introducing formulation or delivery differences. Such an applicant would still need to address listed patents and applicable exclusivity.

How does US 7,470,433 compare with competing estradiol gel patent estates?

Estradiol gel products do not necessarily share the same formulation or patent estate. Commercial products may differ in alcohol content, permeation enhancers, carbomer systems, metered-dose pumps, application volume, and labeling.

Product category Typical formulation issue Relationship to US 7,470,433
Estradiol hydroalcoholic gel Ethanol, water, carbomer, glycols Potentially close if it uses the claimed glycol ether
Estradiol gel without glycol ether Alternative penetration system Potential design-around
Estradiol emulsion or cream Oil phase, fatty excipients, emulsion system Often outside the claimed gel architecture
Estradiol spray Metered spray and volatile vehicle Usually outside the claimed gel claims
Estrogen-progestin product Combined hormonal therapy Potentially outside the no-progestin limitation
Estradiol patch Polymer matrix or reservoir delivery Outside the gel claims

The most important competitive distinction is whether the product uses diethylene glycol monoethyl ether. That ingredient, combined with ethanol and propylene glycol, places a product closer to claims 13 through 18.

What manufacturing and formulation barriers remain?

The patent does not protect every manufacturing process for estradiol gel. It primarily protects the finished formulation. A manufacturer may avoid the patent while producing a clinically equivalent product through a different vehicle.

Practical barriers include:

  • Achieving consistent estradiol content at low concentration.
  • Maintaining carbomer viscosity across production lots.
  • Neutralizing the gel to the required pH without precipitation or phase instability.
  • Controlling alcohol evaporation during filling and packaging.
  • Preventing adsorption of estradiol to equipment or packaging.
  • Demonstrating dose uniformity from the final container.
  • Establishing bioequivalence for a topical product.
  • Managing skin irritation and absorption variability.
  • Preserving formulation performance after repeated package opening.

These technical requirements can create commercial barriers even after patent expiry. They are regulatory and manufacturing barriers, not substitutes for patent rights.

What licensing deals and ownership issues affect the patent?

Patent ownership and product commercialization are separate diligence issues. A patent may have been assigned, licensed, or included in a broader transaction involving the estrogen product, while the FDA application is held by a different entity.

A complete ownership review should track:

  • Original named inventors.
  • Original assignee.
  • USPTO assignment records.
  • Any exclusive license covering estrogen gels.
  • NDA ownership and approved-product holder.
  • Current commercial distributor.
  • Litigation standing and rights to enforce.
  • Any covenant not to sue or settlement affecting generic entry.

The patent itself does not establish the terms of a license agreement. Public assignment records establish chain of title, but private license economics, royalty rates, field restrictions, and settlement terms may not be fully public.

What litigation and settlement issues should generic entrants evaluate?

A generic entrant should search federal litigation records for:

  • ANDA notices involving the relevant estradiol gel NDA.
  • Declaratory-judgment actions.
  • Hatch-Waxman infringement complaints.
  • Motions concerning claim construction.
  • Patent-term disputes.
  • Settlement agreements filed under the Medicare Modernization Act.
  • FTC or court review of reverse-payment provisions.

The most material litigation issue would be whether the accused product contains the same functional excipient combination. A product with estradiol alone is not enough for infringement. The plaintiff would need to prove each required formulation element or establish infringement under the doctrine of equivalents.

What generic launch scenarios exist?

Three launch scenarios are commercially plausible.

Launch after patent expiry

This is the lowest litigation-risk route. The applicant can certify Paragraph II if the listed patent has expired, subject to any separate patents, exclusivity periods, pediatric extensions, or regulatory barriers.

Paragraph IV launch after litigation

The applicant may launch after prevailing in litigation, obtaining dismissal, or benefiting from a statutory or court-imposed resolution. Exposure includes damages, an injunction, and potential launch disruption.

Formulation design-around

The applicant can develop a gel that avoids at least one required limitation, such as:

  • No diethylene glycol monoethyl ether.
  • A different penetration enhancer.
  • No propylene glycol.
  • A different dosage form.
  • A formulation containing a progestin, if clinically appropriate.
  • A non-gel delivery system.

A design-around must address both literal infringement and the doctrine of equivalents. It also must satisfy FDA requirements independently.

How strong is the patent estate?

The estate is strongest against an estradiol gel that substantially replicates the claimed ethanol, propylene glycol, diethylene glycol monoethyl ether, carbomer, and water system. Claims 13 and 18 are especially relevant to that product profile.

The estate is weaker against:

  • Estradiol creams.
  • Patches.
  • Sprays.
  • Gels using a different permeation enhancer.
  • Combination estrogen-progestin products.
  • Formulations outside the claimed excipient ranges.
  • Products introduced after expiration.

The broadest claims provide scope, but their breadth increases potential exposure to prior-art, enablement, written-description, and indefiniteness challenges.

Key Takeaways

  • US 7,470,433 protects estrogen-containing transdermal or transmucosal gels, not estradiol as a molecule.
  • The central formulation combination is ethanol or another C2-C4 alkanol, a polyalcohol, and a monoalkyl ether of diethylene glycol.
  • Propylene glycol and diethylene glycol monoethyl ether are the key limitations in claims 13 through 18.
  • The claims exclude progestins and substantially exclude long-chain fatty alcohols, fatty acids, and fatty esters.
  • Claim 12 recites a detailed estradiol, carbomer, alcohol, propylene glycol, and glycol-ether formulation.
  • Generic applicants would face formulation-patent analysis, not biosimilar analysis.
  • Paragraph IV risk would focus on non-infringement, obviousness, written description, enablement, and claim-construction issues.
  • Patent enforceability depends on the exact USPTO term record, including patent-term adjustment, extensions, and disclaimers.
  • The patent is most relevant to hydroalcoholic estradiol gels that use diethylene glycol monoethyl ether.
  • Products using different delivery systems or penetration enhancers may have meaningful design-around positions.

FAQs

Does US 7,470,433 cover all estradiol gels?

No. It covers estradiol gels only when they contain the required vehicle, permeation enhancer, gelling system, and other claim limitations. An estradiol gel using a different penetration enhancer may fall outside the literal claims.

Is Transcutol the same as diethylene glycol monoethyl ether?

Yes. Transcutol is a common trade name for diethylene glycol monoethyl ether, also known as ethoxydiglycol. Its presence is particularly important under claims 13 through 18.

Can a generic use ethanol and propylene glycol without infringing?

Potentially, but the answer depends on the complete formulation. If the generic also uses diethylene glycol monoethyl ether, a carbomer gel, estrogen, and the claimed concentration ranges, infringement risk increases substantially.

Does FDA approval prove infringement of the patent?

No. FDA approval addresses safety, efficacy, quality, and regulatory requirements. Patent infringement is determined under patent law by comparing the accused product with the properly construed claims.

Does the patent cover estrogen patches?

Generally no. The claims are directed to gel formulations for transdermal or transmucosal administration. A patch product would not ordinarily satisfy the gel limitation, although separate patents could cover patch technology.

References

  1. United States Patent and Trademark Office. (n.d.). 35 U.S.C. § 154: Contents and term of patent; provisional rights. https://www.uspto.gov/web/offices/pac/mpep/mpep-2700.pdf

  2. United States Patent and Trademark Office. (2008). U.S. Patent No. 7,470,433, transdermal and transmucosal formulations. Patent Center. https://patentcenter.uspto.gov/

  3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

  4. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda/abbreviated-new-drug-application-anda

  5. U.S. Code. (n.d.). 21 U.S.C. § 355: New drugs. https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section355&num=0&edition=prelim

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 7,470,433

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,470,433

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
PCT/EP00/07533Aug 03, 2000

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.